Skip to main content

Advertisement

Table 1 Patient data and characteristics of 34 MuscleChip expression profiles.

From: Sources of variability and effect of experimental approach on expression profiling data interpretation

Patients/ Arrays Individual or Mixed Age (years) Stage of histopathology Scaling Factor % Present Calls % Diff Calls Paired samples Four comparisons > 2-fold changes relative to controls 1a, 1b
1a Ind 5.5 mid 1.08 51 5.6 302
1b     0.9 50   
2a Ind 4.5 early stage 1.93 38 3 427
2b     3.28 36   
3a Ind 5 early/mid stage 0.53 49 8.6 312
3b     0.97 44   
3a-dup Ind 5 early/mid stage 0.46 50 0.8 N/A
3b-dup     0.82 46 2.1  
4a Ind 6 mid 0.78 51 18 324
4b     1.02 50   
5a Ind 5 early 1.26 51 6.2 453
5b     2.13 40   
6a Ind 12 mid 2.72 35 1.5 305
6b     2.46 38   
7a Ind 11 mid/moderate 0.79 51 2.6 356
7b     0.9 49   
8a Ind 10 mid 1.24 49 1.5 463
8b     1.74 50   
9a Ind 11 variable 1.04 50 8.5 266
9b     1.37 46   
10a Ind 10 mid/late 0.48 52 1.5 250
10b     0.75 48   
6-9mix-1a mix 6 to 9 5 patients biopsies, cRNAs mixed 0.82 49 3.2 289
6-9mix-1b mix    1.16 55   
5-6mix-1a mix 5 to 6 5 patients biopsies, cRNAs mixed 0.67 60 0.5 486
5-6mix-1b mix    1.03 58   
10-12mix-1a mix 10 to 12 5 patients biopsies, cRNAs mixed 0.82 49 0.4 388
10-12mix-1b mix    1.16 55   
control 1a mix 6 to 9 5 normal biopsies, cRNAs mixed 0.71 53 1.5 N/A
control 1b mix    0.48 54   
control 2a mix 5 to 12 3 normal biopsies, cRNAs mixed 0.86 54 0.8 N/A
control 2b mix    0.78 53   
control 3a mix 4 to 13 3 normal biopsies, cRNAs mixed 0.95 51 1.1 N/A
control 3b mix    0.78 55